Dr. Stone Discusses Monitoring MRD in AML

(1:34)

The role of MRD in AML regulatory decision making

(3:27)

Dr. Konopleva on the Controversies Surrounding MRD in AML

(4:53)

MRD in myeloma: the FDA perspective

(1:26)

Current role of MRD in AML

(1:12)

The emerging role of MRD in colorectal cancer decision making

(2:53)

Approaches to and the use of MRD in ALL

(5:17)

Top 1 M82B/AWM malaysia without scope

(1:40:6)

Developments for the use of MRD in AML

(1:17)

ClonoSEQ: evaluating MRD in CLL

(2:54)

The role of MRD in AML

(4:22)

Approaching MRD in Multiple Myeloma

(23:32)

The current role of MRD in AML and challenges with implementing this in clinical practice

(1:26)

The prognostic and therapeutic implications of MRD in AML

(2:59)

The real world utilization of MRD in myeloma across Europe

(1:27)

The importance of MRD in AML prognosis and therapy

(2:16)

The prognostic value of MRD in multiple myeloma \u0026 MRD-guided therapy

(4:16)

MRD in AML: ELN recommendations

(2:45)

Measurable Residual Disease in Acute Myeloid Leukemia MRD in AML

(34:52)